Afatinib: Emerging next-generation tyrosine kinase inhibitor for NSCLC

Valerie Nelson, Jacqueline Ziehr, Mark Agulnik, Melissa Johnson*

*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

105 Scopus citations

Fingerprint

Dive into the research topics of 'Afatinib: Emerging next-generation tyrosine kinase inhibitor for NSCLC'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science